91AV

This conference focuses on the design parameters, synthesis and clinical validation of new drug delivery vehicles, and is designed to bridge the gap between basic science and unmet clinical needs with a particular focus on gene editing therapeutics, RNA therapeutics, sustained release technologies and immuno-engineering. Several new polymers, linkers, proteins, and nanoparticles for drug delivery will be presented, as well as recent clinical trial data generated from drug delivery companies that are pioneering the development of new experimental therapeutics. The field is rapidly evolving and it is having a significant clinical impact but there are still a number of challenges associated with accelerating the pace in transitioning into the clinic. Recent advances in chemistry, genetics and biochemistry have majorly impacted drug delivery based therapeutics and this conference aims to make these new developments accessible to a broad audience.

Key Sessions
•    Therapeutic gene editing
      - Fundamentals of gene editing and overview of gene editing modalities (protein, gene, mRNA, viral, etc.)
      - New gene editing modalities
      - Approaches to delivery of therapeutic gene editing modalities – in vivo, ex vivo
•    Extrahepatic delivery of nucleic acids
•    Characterization of therapeutic nanoparticles and control strategies for manufacturing
      - Molecular characterization
      - Physchem characterization
      - Toxicological characterization
      - New methods
      - Case studies from industry
•    New linkers for triggered or controlled release
•    New long acting technologies
•    Tumor targeting with nanoparticles, recent progress and challenges